Literature DB >> 26669245

GPR55 - a putative "type 3" cannabinoid receptor in inflammation.

Hyewon Yang, Juan Zhou, Christian Lehmann.   

Abstract

G protein-coupled receptor 55 (GPR55) shares numerous cannabinoid ligands with CB1 and CB2 receptors despite low homology with those classical cannabinoid receptors. The pharmacology of GPR55 is not yet fully elucidated; however, GPR55 utilizes a different signaling system and downstream cascade associated with the receptor. Therefore, GPR55 has emerged as a putative "type 3" cannabinoid receptor, establishing a novel class of cannabinoid receptor. Furthermore, the recent evidence of GPR55-CB1 and GPR55-CB2 heteromerization along with its broad distribution from central nervous system to peripheries suggests the importance of GPR55 in various cellular processes and pathologies and as a potential therapeutic target in inflammation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26669245     DOI: 10.1515/jbcpp-2015-0080

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  31 in total

1.  Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis.

Authors:  Jeremy D Hill; Viviana Zuluaga-Ramirez; Sachin Gajghate; Malika Winfield; Yuri Persidsky
Journal:  Br J Pharmacol       Date:  2018-07-04       Impact factor: 8.739

Review 2.  Cannabinoids in the descending pain modulatory circuit: Role in inflammation.

Authors:  Courtney A Bouchet; Susan L Ingram
Journal:  Pharmacol Ther       Date:  2020-01-29       Impact factor: 12.310

Review 3.  The Roles of Orphan G Protein-Coupled Receptors in Autoimmune Diseases.

Authors:  Mingming Zhao; Zheyu Wang; Ming Yang; Yan Ding; Ming Zhao; Haijing Wu; Yan Zhang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-07       Impact factor: 8.667

Review 4.  The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.

Authors:  Stefania Petrosino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2016-09-29       Impact factor: 8.739

5.  A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity.

Authors:  Katrina Hurst; Corinne Badgley; Tanner Ellsworth; Spencer Bell; Lindsey Friend; Brad Prince; Jacob Welch; Zack Cowan; Ryan Williamson; Chris Lyon; Brandon Anderson; Brian Poole; Michael Christensen; Michael McNeil; Jarrod Call; Jeffrey G Edwards
Journal:  Hippocampus       Date:  2017-06-27       Impact factor: 3.899

Review 6.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

7.  THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner.

Authors:  Marc Richard Kolbe; Tim Hohmann; Urszula Hohmann; Chalid Ghadban; Ken Mackie; Christin Zöller; Julian Prell; Jörg Illert; Christian Strauss; Faramarz Dehghani
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639

8.  Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch.

Authors:  Fabienne Briand-Mésange; Véronique Pons; Sophie Allart; Julien Masquelier; Gaëtan Chicanne; Nicolas Beton; Bernard Payrastre; Giulio G Muccioli; Jérôme Ausseil; Jean-Luc Davignon; Jean-Pierre Salles; Hugues Chap
Journal:  J Biol Chem       Date:  2020-09-11       Impact factor: 5.157

Review 9.  Targeting of G-protein coupled receptors in sepsis.

Authors:  Abdul Rehman; Noor Ul-Ain Baloch; John P Morrow; Pál Pacher; György Haskó
Journal:  Pharmacol Ther       Date:  2020-03-19       Impact factor: 12.310

10.  Haematopoietic and cardiac GPR55 synchronize post-myocardial infarction remodelling.

Authors:  Sarah-Lena Puhl; Michael Hilby; Michael Kohlhaas; Linus M Keidel; Yvonne Jansen; Michael Hristov; Jakob Schindler; Christoph Maack; Sabine Steffens
Journal:  Sci Rep       Date:  2021-07-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.